PROGRESS AND PROSPECTS IN CANCER RESEARCH: THERAPEUTIC INNOVATION AND DIAGNOSTIC EVOLUTION

Cancer research has undergone unprecedented acceleration in recent years due to advances in molecular biology, immunology, genomics, and artificial intelligence. The period from 2024 to 2025 has been particularly significant, marked by the approval of novel anticancer agents, progress in personalized immunotherapy, rapid development of antibody–drug conjugates, mRNA-based cancer vaccines, liquid biopsy technologies, and AI-driven diagnostics. These innovations have enhanced tumor specificity, improved survival outcomes, and reduced systemic toxicity. This comprehensive review critically evaluates the most recent advancements in cancer research, emphasizing translational relevance, clinical applicability, and emerging challenges such as drug resistance, tumor heterogeneity, and healthcare accessibility. The review aims to provide pharmacy and biomedical researchers with a detailed overview of contemporary oncology research and its future trajectory.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-01-16
DOI
https://doi.org/10.5281/zenodo.18267224
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

PROGRESS AND PROSPECTS IN CANCER RESEARCH: THERAPEUTIC INNOVATION AND DIAGNOSTIC EVOLUTION

Ms. Mugdha Jagdishbhai Dhimar1*, Ms. Ayushi Sanjaykumar Chokshi2, Mr. Jimitkumar Bharatbhai Prajapati3, Mr. Vandit Ashwinbhai Moradiya4, Mr. Vipul Bhurabhai Chaudhary5, Mr. Dhruv Mukeshbhai Makwana6
Zenodo (CERN European Organization for Nuclear Research)
Cancer Immunotherapy and Biomarkers
article

PROGRESS AND PROSPECTS IN CANCER RESEARCH: THERAPEUTIC INNOVATION AND DIAGNOSTIC EVOLUTION

Ms. Mugdha Jagdishbhai Dhimar1*, Ms. Ayushi Sanjaykumar Chokshi2, Mr. Jimitkumar Bharatbhai Prajapati3, Mr. Vandit Ashwinbhai Moradiya4, Mr. Vipul Bhurabhai Chaudhary5, Mr. Dhruv Mukeshbhai Makwana6
article en

Abstract

Cancer research has undergone unprecedented acceleration in recent years due to advances in molecular biology, immunology, genomics, and artificial intelligence. The period from 2024 to 2025 has been particularly significant, marked by the approval of novel anticancer agents, progress in personalized immunotherapy, rapid development of antibody–drug conjugates, mRNA-based cancer vaccines, liquid biopsy technologies, and AI-driven diagnostics. These innovations have enhanced tumor specificity, improved survival outcomes, and reduced systemic toxicity. This comprehensive review critically evaluates the most recent advancements in cancer research, emphasizing translational relevance, clinical applicability, and emerging challenges such as drug resistance, tumor heterogeneity, and healthcare accessibility. The review aims to provide pharmacy and biomedical researchers with a detailed overview of contemporary oncology research and its future trajectory.

Zenodo (CERN European Organization for Nuclear Research)
Industry, innovation and infrastructure
Openalex Percentile: Top 86%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.